Concern at delayed access to Covid prevention treatment

AstraZeneca's Evusheld is a Covid-19 antibody drug for people with serious health problems or allergies who cannot get adequate protection from vaccination. Picture: AstraZeneca via AP

Patient advocates have raised concerns over delayed access to a treatment preventing Covid-19 and the decision to limit eligibility for boosters. 

Vulnerable patients have called for faster evaluation of Evusheld, from AstraZeneca.